Huons Global휴온스글로벌
084110 · KOSDAQ · ₩084110 · 휴온스글로벌
- Market cap
- ₩272B
- Enterprise value
- ₩374B
- P/E
- 12.1×
- P/B
- 0.5×
- Dividend yield
- 4.1%
- ROE
- 4.1%
- Net margin
- 2.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.0% from the high
₩20,100Today: ₩21,400 – ₩22,350₩76,700
Returns
- 1W+0.9%
- 1M−1.4%
- 3M+4.4%
- 6M−67.3%
- YTD−58.0%
- 1Y−63.1%
- Volume today
- 25,820
- 0.9× the 20-day average
- Traded today
- ₩563M
- Listed shares
- 12,659,812
- EPS (12 months)
- ₩1,783
- Earnings yield 8.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only a routine filing notice about an asset acquisition, with no further detail. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0.9% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Huons Global stock overview
Huons Global (휴온스글로벌, KRX: 084110) is listed on KOSDAQ, in the Biotech & Pharma sector. Hugens Global is a pure holding company in the Hugens Group, a Korean total healthcare business that owns and controls subsidiaries rather than directly running most operations. Its shares closed at ₩21,500 on Oct 28, 2026, down 2.05% on the day, giving it a market value of ₩272B.
Key facts
- Market cap
- ₩272B
- Sector
- Biotech & Pharma
- Latest price change
- −2.05%
- As of
- Oct 28, 2026
- Main business
- Hugens Global is a pure holding company in the Hugens Group, a Korean total healthcare business that owns and controls subsidiaries rather than directly running most operations.
Quick answers about Huons Global
- What does Huons Global do?
- Hugens Global is a pure holding company in the Hugens Group, a Korean total healthcare business that owns and controls subsidiaries rather than directly running most operations. Its income comes mainly from brand royalties, management consulting and shared-service fees, rental income and dividends from its subsidiaries. Subsidiaries cover pharmaceuticals, biopharmaceutical R&D, dermatology and aesthetics (hyaluronic acid fillers and botulinum toxin), medical devices, health functional foods, glass vials and ampoules for drug packaging, and cosmetic packaging components, and they serve domestic and overseas customers including licensing and contract manufacturing for other drugmakers.
- What is the market cap of Huons Global?
- The market capitalisation of Huons Global was ₩272B at the close on Oct 28, 2026.
- Who are the largest shareholders of Huons Global?
- According to the latest official filings, the largest reported holders are Yoon Seong-tae (57.14%, as of Nov 21, 2025); Yoon In-sang (4.63%, as of Feb 28, 2025); National Pension Service (0.64%, as of Dec 31, 2025).
- When is the next earnings report from Huons Global?
- Korean companies rarely announce results dates in advance. Based on when Huons Global filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Huons Global?
- Yes. The National Pension Service held 0.64% of Huons Global shares as of Dec 31, 2025.
Company profile
Hugens Global is a pure holding company in the Hugens Group, a Korean total healthcare business that owns and controls subsidiaries rather than directly running most operations. Its income comes mainly from brand royalties, management consulting and shared-service fees, rental income and dividends from its subsidiaries. Subsidiaries cover pharmaceuticals, biopharmaceutical R&D, dermatology and aesthetics (hyaluronic acid fillers and botulinum toxin), medical devices, health functional foods, glass vials and ampoules for drug packaging, and cosmetic packaging components, and they serve domestic and overseas customers including licensing and contract manufacturing for other drugmakers.
Written by AI from the company's latest annual report.
- Korean name
- 휴온스글로벌
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- Song Soo-young, Yoon Sung-Tae (Independent representation)
- Founded
- Jul 1987
- Listed
- Dec 2006
- Listed shares
- 12,659,812
- Fiscal year ends
- Month 12
- Website
- www.huonsglobal.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Major Matters Report (Decision on Acquisition of Tangible Assets)Oct 27, 2026
- Not Designated as Unfaithful Disclosure Company (Designation Deferred)Oct 21, 2026
- Designation of Unfaithful Disclosure Company Notice (Retraction of 3 Disclosures)Sep 23, 2026
- Shareholders' meeting calledAug 26, 2026
- [Correction] Ad Hoc Disclosure Obligation-Related Matters (Fair Disclosure) (Notice of Withdrawal of Plan for In-Kind Dividend to Enhance Shareholder Value)Aug 26, 2026
Titles in Korean until English translations are added.
Also known as: Huons Global / 휴온스글로벌 / 084110 / KRX:084110
Source: KRX statistical information